Breaking the barrier holding Western immunotherapies back. For advanced Gastric and GEJ cancers where standard lines have failed.
For a decade, CAR-T cell therapy was locked behind blood cancers, blocked by complex microenvironments. China’s NMPA changed this by greenlighting satri-cel (CT041) for gastrointestinal cancers.
Stomach cancer, or gastric cancer, develops when malignant cells grow uncontrollably in the lining of the stomach. It is a serious global health issue and often goes undetected in the early stages due to vague symptoms like indigestion or appetite loss. As a result, many patients are diagnosed when the disease has already advanced, making treatment more difficult.
Standard treatment options such as surgery, chemotherapy, radiation, and targeted therapies can be effective, especially if the cancer is caught early. However, in advanced cases, these treatments often lose effectiveness, and patients may experience harsh side effects. Drug resistance and disease relapse are common, highlighting the need for more durable and targeted treatment strategies.
Given the high recurrence rate and limited outcomes of existing treatments, there is a growing demand for innovative therapies that can offer better results with fewer side effects. Patients with relapsed or treatment-resistant stomach cancer especially need more effective and personalized options.
CAR-T cell therapy is a groundbreaking form of immunotherapy that reprograms a patient’s immune cells to recognize and attack cancer. While it has shown remarkable success in certain blood cancers, ongoing research is now exploring its potential in treating solid tumors like stomach cancer. For patients with few remaining options, CAR-T therapy offers new hope—targeted, personalized, and potentially long-lasting.
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an advanced type of immunotherapy that uses a patient’s own immune cells to fight cancer. In this treatment, T cells—a type of white blood cell—are collected from the patient, genetically modified in a lab to express special receptors (CARs) that can recognize cancer cells, and then infused back into the patient. These engineered T cells are designed to seek out and destroy cancer cells with precision.
CAR-T therapy has achieved remarkable success in treating certain blood cancers, such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. Several CAR-T products have been approved worldwide, offering durable remission and, in many cases, hope for patients who had no other treatment options. This has positioned CAR-T as one of the most significant advances in hematologic oncology in recent years.
Expanding CAR-T therapy to treat solid tumors like stomach cancer has been more challenging due to barriers such as tumor heterogeneity, the suppressive tumor microenvironment, and difficulty in identifying safe, specific targets. However, recent advances in CAR design, combination strategies (e.g., checkpoint inhibitors), and local delivery techniques are opening new possibilities. Early-stage clinical trials in gastric, pancreatic, and other solid tumors are now underway, with promising signs of safety and initial anti-tumor activity.
For patients with advanced or treatment-resistant stomach cancer, CAR-T cell therapy represents a potential new frontier. Researchers are actively developing CAR-T therapies that target stomach cancer-specific antigens like Claudin 18.2, HER2, and others. Though still in early clinical stages, this approach offers hope for more effective and personalized treatments where conventional therapies may no longer work.
CAR-T cell therapy may be an option for patients with advanced or metastatic gastric (stomach) cancer, especially when standard treatments are no longer effective. Eligibility is determined through a careful medical evaluation by your oncology team.
To be considered for CAR T therapy, patients typically need to meet the following criteria:
A confirmed diagnosis of advanced or metastatic gastric cancer
Disease progression after standard treatments such as chemotherapy or targeted therapy
Sufficient organ function (such as heart, liver, and kidney health) to tolerate the treatment
Overall health status that allows for the intensive nature of CAR T cell therapy
Each case is unique. Your oncologist will carefully review your medical history, current condition, and previous treatments to decide if CAR T therapy is a suitable and safe option for you.
China has emerged as a global leader in CAR-T cell therapy research, particularly in the field of gastric (stomach) cancer. Significant progress has been made in developing CAR-T cells that target Claudin 18.2, a promising tumor-associated antigen expressed in many gastric cancers. Early-phase clinical trials conducted in China have demonstrated encouraging safety profiles and early signs of clinical efficacy.
Chinese biotech companies are driving innovation by developing dual-targeting CAR-T cells, optimizing dosing strategies, and exploring combination therapies to enhance treatment outcomes. Strong government support, streamlined regulatory pathways, and substantial investment in biotech research have created a fertile environment for rapid advancement.
Several ongoing clinical trials in China are exploring CAR-T therapies targeting Claudin 18.2, HER2, and other gastric cancer markers. These trials are not only testing the safety and effectiveness of new CAR constructs but are also investigating how to best integrate CAR-T cell therapy into broader treatment regimens for stomach cancer.
With its growing expertise, infrastructure, and innovation, China is well-positioned to lead the next wave of breakthroughs in CAR-T cell therapy for solid tumors such as gastric cancer.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.